Baudax Bio Inc (BXRXQ)

Market Cap	84.73K
Revenue (ttm)	310,000
Net Income (ttm)	-7.16M
Shares Out	7.99M
EPS (ttm)	83.80
PE Ratio	0.00
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	16,443
Open	0.0108
Previous Close	0.0110
Day's Range	0.0106 - 0.0206
52-Week Range	n/a
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About BXRXQ

Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care related settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with other non-NSAID analgesics. It also develops BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMB, which is in phase I clinical trial, as well as a proprietary blockade reversal agent; and BX3000, a NMB revers...

• Industry: Biotechnology
• Sector: Healthcare
• Employees: 9
• Stock Exchange: OTCMKTS
• Ticker Symbol: BXRXQ

Financial Performance

In 2022, Baudax Bio's revenue was $1.27 million, an increase of 17.50% compared to the previous year's $1.08 million. Losses were -$58.80 million, 197.4% more than in 2021.